Novartis AG (NVS) exhibits 45.0% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.0x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 13.9% operating margin and 9.9% ROIC, outpacing sector cost of capital.
ROIC: 9.9% // GM: 45.0%YoY revenue trajectory of +15.4% paired with 2.21% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +15.4% // FCF YLD: 2.21%Altman Z-Score of 3.74 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.74 // F-SCORE: 8/9Trading at 32.8x trailing P/E (27.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 32.8x // EV/EBITDA: 21.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $160.79 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 10.9% net margins.
NET MARGIN: 10.9% // D/E: 0.39x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NVS & activate live FRED threshold breach alerts.